Ondine to present Steriwave analysis at Geneva conference

(Sharecast News) - Ondine Biomedical said in an update on Wednesday that its health economic analysis of Steriwave nasal photodisinfection would be presented at the 12th International Conference on Prevention & Infection Control (ICPIC) in Geneva after being selected for an oral session at the event. The AIM-traded infection prevention company said the abstract, produced with the York Health Economics Consortium, highlighted how Steriwave use in surgical patients can reduce the costs and incidence of surgical site infections.

Data from Mid Yorkshire Teaching NHS Trust, alongside two separate economic models using broader literature, showed the treatment improves outcomes and delivers significant savings by preventing infections in major surgeries.

"These results are significant for hospital administrators and patients alike, especially with the unprecedented strain on healthcare systems worldwide. Preventing infections is not just about patient safety, it is a critical strategy for conserving resources, improving hospital efficiency, and combating antimicrobial resistance," said Simon Sinclair, Ondine's chief medical officer.

"The Mid Yorkshire data, combined with our rigorous economic modeling, shows how a simple, rapid intervention like Steriwave can have a profound impact on patient outcomes and reduce the economic burden of surgical site infections."

At 0929 BST, shares in Ondine Biomedical were up 2.33% at 15.35p.

Reporting by Josh White for Sharecast.com.